EGI
ALDX icon

EAM Global Investors’s Aldeyra Therapeutics ALDX Stock Holding History

EAM Global Investors’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-140,198
Closed -$1.59M – 190
2021
Q2 		$1.59M Buy
+140,198
New +$1.69M 0.44% 130
2019
Q1 		– Sell
-127,912
Closed -$1.06M – 126
2018
Q4 		$1.06M Buy
127,912
+41,298
+48% +$423K 0.58% 91
2018
Q3 		$1.2M Buy
+86,614
New +$703K 0.48% 115

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM

EAM Global Investors's ALDX Position: Q3 2021 in Review

EAM Global Investors sold out of Aldeyra Therapeutics (ALDX) in Q3 2021, closing a stake of 140,198 shares — an estimated $1.59M sold.

EAM Global Investors first reported a position in ALDX in Q3 2018 and held it in 3 quarters. The position peaked at $1.59M in Q2 2021. 117 funds tracked by Wall St. Rank hold ALDX as of Q3 2021.

  • EAM Global Investors reported no remaining Aldeyra Therapeutics position as of Q3 2021 after selling out during the quarter.
  • EAM Global Investors sold 140,198 Aldeyra Therapeutics shares in Q3 2021, an estimated $1.59M.
  • EAM Global Investors first reported a position in Aldeyra Therapeutics in Q3 2018 and held it in 3 quarters.
  • EAM Global Investors's Aldeyra Therapeutics position peaked at $1.59M in Q2 2021.
  • 117 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q3 2021.

Based on EAM Global Investors's 13F filing for Q3 2021, filed 12 Nov 2021.